PhD: Understanding Endometriosis Mechanisms Through Drug Discovery

PhD: Understanding Endometriosis Mechanisms Through Drug Discovery

Quick Decision

Which effects of a compound reveal a disease mechanism rather than a general anti-inflammatory response? This project uses chemical analogues to investigate that question in endometriosis, connecting medicinal chemistry with macrophage biology. It does not promise a patient-ready medicine during the PhD. The project advert names Professor Erin Greaves, Dr Alex Baker and Dr David Fox across Warwick Medical School and Chemistry; Fox's precise role and the division of chemical and biological work remain unclear. Greaves MIBTP profile, MIBTP project listing.

Applicants may draw on chemical synthesis/SAR, pharmacology, inflammatory biology or disease models, provided they can explain their interest in the chemical and biological sides of the work. Chinese mainland applicants use the international route and remain subject to institutional recognition and individual qualification assessment. Warwick tops up the overseas tuition difference for successful MIBTP awardees. Up to 30% of awards in an MIBTP cohort may go to international applicants; whether that cohort covers the entire partnership remains unconfirmed. This is a cohort-level proportion, not this project's award allocation or an individual's chance; the project-specific number of awards is unconfirmed. The listed deadline is 23 November 2026 and the start is October 2027; the application opening date, closing time and time zone are unstated, and current acceptance status is unconfirmed. Application and fee support, China qualification guidance.

Research Problem and Doctoral Work

Endometriosis involves endometrium-like tissue outside the uterus and chronic inflammatory symptoms, including pelvic pain and infertility. WHO estimates about 10% of reproductive-age women are affected and emphasises limited diagnosis/treatment access and no known cure. This establishes substantial unmet need, not evidence that a particular immune target is already clinically validated. WHO disease context.

The advertised starting point is an unnamed small molecule tested preclinically. The student will design and synthesise analogues, map structure–activity relationships, refine successful compounds through QSAR and other in-silico techniques, identify/validate relevant targets and investigate effects in cells and animals. NLRP3, KEAP1/Nrf2 and macrophage activity are explicit priorities. Biological endpoints include inflammation, macrophage function and lesions. No starting structure, assay panel, animal species, numerical throughput or software is supplied. The identity of the starting compound remains unconfirmed.

The important inferential problem is separating a molecule’s general anti-inflammatory effects from a mechanism that matters in endometriosis. SAR can show which structural changes alter activity; it does not alone prove target engagement or explain every downstream effect. Changes in cell viability, target selectivity, model phenotype and disease endpoints would require separate interpretation. These are research-design considerations, not an additional operational protocol or newly imposed admission requirements.

The strongest potential output is a defensible link from chemical features through target/pathway engagement to a disease-relevant phenotype. A useful negative result could show that an apparent pathway effect fails in a more representative model. It would still inform mechanism. A thesis is not obliged to deliver a clinical candidate, a completed clinical trial or a cure.

School, Programme and Field Context

University of Warwick is the confirmed registering university, with research across the Medical School and Chemistry. MIBTP’s six partner universities provide a training network, not evidence of a joint/double degree. This is a four-year studentship rather than a verified employment contract. Warwick ranks equal 68 in QS 2027 overall; Chemistry reports ninth UK research power in REF 2021. These are scoped institutional/departmental indicators. No independently verified Medical School-specific rank is claimed. QS2027 table, Chemistry environment.

MIBTP combines doctoral research with quantitative training, partner experience, masterclasses and a three-month PIPS placement. The detailed public timetable remains labelled 2025, so it describes the model rather than the settled 2027 calendar. The exact 2027 programme, final departmental degree title and placement arrangements should be confirmed. Warwick applications go through School of Life Sciences MIBTP DTP P-C1PBB, despite the medical/chemistry research location; do not substitute an ordinary department PhD route. Published training model.

Supervisors, Papers and Research Conditions

Greaves’ laboratory uses patient biopsies, cell models and an endometriosis mouse model to study macrophage origins, heterogeneity and nerve interactions. The MIBTP profile specifies training from the supervisor, experienced postdocs and lab manager, with at least weekly scheduled meetings. This supports an established experimental environment, while project-specific sample access, ethical approvals and assay capacity still need confirmation. Greaves laboratory.

Baker’s official MIBTP profile emphasises chemical solutions to neglected/humanitarian problems, hands-on early training and progression to independent research. It describes weekly group and monthly individual meetings. His other peptide-discovery/diagnostic projects are not work packages of this endometriosis project. David Fox is explicitly named on the advert, but his precise contribution and the chemistry/biology supervision split remain unconfirmed. Baker profile.

Recent papers: one original study and two reviews

The three papers provide experimental, model-review and mechanism-review context; their individual evidence limits are stated below.

Henlon et al., 2024, PNAS 121:e2405474121.

Greaves’ team combines single-cell analysis and human–mouse comparison to distinguish disease-promoting and pro-resolving macrophage states. The implication is that blanket macrophage suppression may miss protective functions; phenotype and tissue context matter. The discussion identifies a single-timepoint snapshot and species-specific populations, limiting conclusions about disease dynamics. The evidence assessed is limited to selected results and discussion in the publication PDF. PNAS original research.

Black et al., 2025, IJMS 26:580.

Greaves coauthors a review comparing cells, 3D systems and animal models. Its useful contribution is model selection: primary cells can change during culture and no model reproduces all human disease. This supports staged validation of a compound rather than equating one cell assay with therapeutic efficacy. Organoids or microfluidics are discussed by the review, but are not promised project resources. The review assessment is limited to its main sections and summary. Model review, main sections and summary.

Wang et al., 2023, Frontiers in Reproductive Health 5:1130849.

This Greaves-coauthored mini-review frames peritoneal macrophage phenotypes and small-vesicle communication as unresolved parts of the disease microenvironment. Its contribution is a mechanistic research framework, not a new drug trial. The evidence here is limited to the publisher introduction and does not validate every cited study. Macrophage/vesicle review.

The combination establishes relevant disease expertise but does not prove NLRP3 or KEAP1/Nrf2 is the single causal bottleneck. Chemistry’s analytical environment, including training-based NMR access, is relevant to compound characterisation; actual project allocations are unknown. The priority discussion is which evidence will discriminate competing mechanisms and which negative controls/independent endpoints the team regards as decisive, without assuming all techniques must already be mastered.

Funding, Application and Living Cost

What is funded and what is still conditional

The MIBTP studentship outline lists UK-rate fees, a tax-free stipend, travel/conference and consumables support, and laptop use. Warwick’s institution-specific rule adds the international tuition difference for successful MIBTP awardees. This resolves the principal overseas-fee gap at programme level; it does not remove the competition or replace a written four-year award letter. The FAQ also states that scholarships follow the strength of the candidate and that an alternative project may be needed if the selected one becomes unavailable. Studentship outline, MIBTP FAQs.

The confirmed 2026/27 UKRI reference is £21,805 annually, or approximately £1,817.08 monthly, with a £5,238 home-fee contribution. Warwick’s table shows £21,830 stipend and £5,258 home fee for 2027/28, but expressly marks future rates as unconfirmed inflation estimates. Thus neither £21,830 nor the application-form funding entry of £5,258 is a guaranteed 2027 living stipend. UKRI confirmed rates, Warwick rates and forecast footnote.

Local budget and upfront cash

The university’s living-cost page is dated October 2025. It gives a £1,171 monthly visa-maintenance benchmark and a separate £13,632 annual example; those figures are arithmetically inconsistent. Neither is a reliable 2027 personal living-cost forecast. Campus rent includes utilities, internet and contents insurance; private accommodation may add utilities, internet and transport. The 2026/27 postgraduate rules require an unconditional firm offer and allocate rooms subject to availability, not a 2027 housing guarantee. Living-cost components, postgraduate housing conditions.

For transparent sensitivity only, a £1,817.08 reference stipend leaves approximately £417.08, £117.08 or a £182.92 deficit against monthly spending of £1,400, £1,700 or £2,000 respectively. These are analyst-selected scenarios, not local rent quotes or promised savings. They exclude upfront immigration/travel costs and depend on the actual 2027 award and accommodation.

The published student immigration health surcharge reference is £776 per visa year; future rates need checking. The granted visa can be longer than the course, and part-year rules affect the total. Visa application costs and travel are additional. The programme’s approximate immigration-cost figure should therefore not be treated as a personalised quotation. IHS rules, Student visa conditions.

Eligibility and submitting the application

Official academic criteria accept a relevant first/high 2:1; a lower 2:1 plus a Master’s or at least three years of relevant postgraduate experience may be considered. Lower results require exceptional additional evidence. A Master’s is not universally mandatory. Mainland Chinese degrees need institution-specific recognition and equivalence; meeting a guide minimum does not imply competitive selection. The linked scoring matrix weights academic record 50%, achievements/experience 40% and references 10%, with independent interview scoring. Its UK percentage bands must not be copied onto Chinese transcripts. Scoring matrix.

Submit the EDI expression of interest and one Warwick application, naming one advertised project and supervisor. A research proposal is not required: CV or personal statement can fill that upload slot. Prepare CV, cover letter, transcripts and references; the FAQ requires at least one academic referee and allows a professional substitute for the second academic reference. Referees are contacted after submission, so their timing matters. Interviews are expected in late January/early February 2027.

English evidence normally must meet the course’s band and test-validity rules. The exact P-C1PBB band was not established. The FAQ allows proof after application but retains an October 2026 start-year sentence, while the advertised intake is October 2027; confirm the actual 2027 evidence deadline. A generic Chemistry course threshold should not silently replace the MIBTP requirement. English requirements.

Applicant Preparation

Official requirements are the MIBTP academic/equivalence and language conditions; the advert does not require every applicant to arrive with synthesis, QSAR, macrophage and animal-model expertise simultaneously. A chemistry-led applicant can show compound characterisation and quantitative SAR reasoning; a biology-led applicant can show careful phenotype interpretation and willingness to learn chemistry. Pure clinical practice ambitions or computational prediction without experimental validation would be a less direct match. These are analytical distinctions, not personal admissions predictions.

Useful preparation is a concise research example that separates observation from causal explanation, identifies an alternative mechanism and shows personal contribution. Explicitly distinguish prior competence from training sought. Animal work, human material and data responsibilities should be discussed rather than presumed.

Career and transferable skills

The skill combination can transfer to discovery pharmacology, medicinal chemistry, translational research and assay/data interpretation. The government’s 2026 Life Sciences Jobs Plan covers discovery through clinical development, manufacturing and digital/regulatory skills; RSC evidence also values practical/digital capability. These are broad sector signals, not endometriosis-specific vacancy counts, salary premiums or visa sponsorship guarantees. Life Sciences Jobs Plan.

Next Actions and Questions to Verify

Before applying: confirm Chinese institution recognition/grade equivalence, the P-C1PBB English band and 2027 proof deadline, exact 23 November closing time and reference receipt requirements. Complete EDI and one Warwick application with the exact project title; proposal is optional under MIBTP rules.

At interview: identify the starting molecule and what prior results can be shared; clarify synthesis/QSAR/biology division and Fox’s role; ask how target engagement, macrophage heterogeneity, general toxicity and lesion endpoints will be distinguished; confirm available human/model resources and training. These questions concern the scientific scope, not a request for a clinical efficacy promise.

Before accepting: obtain written four-year overseas-fee coverage and confirmed 2027 stipend/research costs; confirm ethical/training arrangements for human and animal work, actual supervisory availability, placement travel support and real housing/immigration budget. MIBTP@warwick.ac.uk handles programme administration; Greaves’ lab lists Erin.Greaves@warwick.ac.uk for research enquiries.

Evidence and Sources

The project information does not establish whether applications are still being accepted or whether a particular applicant meets the eligibility criteria. Financial and immigration figures are year-specific references, not confirmed 2027 personal terms. The evidence limits for the three papers are stated individually above.

Project-specific science and career evidence

• Official endometriosis drug-discovery project and Greaves supervision
• Greaves laboratory: macrophage heterogeneity and endometriosis
• Alex Baker MIBTP research and supervision profile
• Henlon et al. 2024: distinct macrophage phenotypes in endometriosis
• Black et al. 2025: Modelling Endometriosis Using In Vitro and In Vivo Systems
• Wang et al. 2023: macrophages and small extracellular-vesicle communication
• WHO endometriosis fact sheet
• MIBTP endometriosis drug-discovery project listing
• UK Life Sciences Jobs Plan

Programme, institution and application evidence

• MIBTP 2027 application and institution-specific fee support
• MIBTP application and studentship FAQs
• MIBTP published training programme
• MIBTP candidate scoring matrix 2026/27
• Warwick postgraduate English-language requirements
• Warwick China Mainland postgraduate entry guidance
• Warwick Chemistry research environment and REF 2021
• Warwick solution-state NMR facility
• QS World University Rankings 2027
• MIBTP current opportunities and studentship outline

Funding and local costs

• UKRI training grant guidance: stipend and fees
• Warwick Doctoral College stipend and fee rates
• Warwick living-cost and housing budget guidance
• Warwick postgraduate accommodation 2026/27
• UK Student visa overview
• Immigration health surcharge costs
• RSC future chemistry workforce and skills evidence